FAILURE_MODE_EXAMPLES = """
<example>
    Flagged Clinical Issue: Prescription of methotrexate without a record of liver function having been measured within the previous 3 months

    MedGuard Patient Summary: The 51‑year‑old male has type 2 diabetes, hypertension (recorded BP up to 156/110 mmHg), psoriatic arthritis, a history of peptic ulcer and is a current smoker (1–15 cigarettes/day). Current repeat medications are amlodipine 10 mg daily, metformin 500 mg BID, atorvastatin 20 mg daily, lansoprazole 30 mg daily, sildenafil PRN, methotrexate 10 mg weekly with folic acid 5 mg weekly, and two topical corticosteroids: betamethasone valerate 0.1% cream and a combination betamethasone 0.1%/fusidic acid 2% cream. Liver function tests were last performed before methotrexate was restarted, so no recent monitoring exists (11 months since last LFTs). The concurrent use of two potent topical steroids raises the risk of local skin atrophy. Atorvastatin and amlodipine together can increase statin concentrations, potentially heightening myopathy risk, though renal function is normal (eGFR ≈ 90 mL/min/1.73 m²). Blood pressure remains above target despite amlodipine monotherapy. Alcohol intake is moderate, which adds hepatotoxic risk while on methotrexate. Overall, the most urgent safety issue is the duplicate high‑potency topical steroid therapy, which can be resolved immediately; liver function monitoring for methotrexate is required but does not constitute a direct medication change.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: No recent liver function monitoring for methotrexate therapy
    Evidence provided by MedGuard: Methotrexate restarted with last LFT performed before restart, with no subsequent LFTs recorded.
    Clinician reasoning: Correct identification - methotrexate requires 3-monthly LFT monitoring and this has lapsed
    The clinician agreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Concurrent use of two high‑potency topical corticosteroids increasing risk of skin atrophy
    Evidence provided by MedGuard: Both betamethasone valerate 0.1% cream and betamethasone 0.1%/fusidic acid 2% cream are listed as repeat medications at the time of the SMR.
    Clinician reasoning: Valid concern - duplicate topical steroids increase local side effect risk
    The clinician agreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Potential statin‑calcium channel blocker interaction (atorvastatin with amlodipine) elevating risk of myopathy
    Evidence provided by MedGuard: Atorvastatin 20 mg daily and amlodipine 10 mg daily are both active; amlodipine can increase atorvastatin plasma concentrations via CYP3A4 inhibition.
    Clinician reasoning: They are both low dose, I wouldn't be concerned - risk is higher with simvastatin or high dose atorvastatin, neither apply here
    The clinician disagreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: MedGuard correctly identified the lapsed LFT monitoring in Issue 1, which directly matches the flagged issue
    correct: true

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: Discontinue the betamethasone valerate 0.1% cream and continue only the betamethasone 0.1%/fusidic acid 2% cream; arrange a follow‑up skin assessment in two weeks to ensure disease control and monitor for any signs of steroid‑induced skin atrophy.

    reasoning: Didn't suggest LFT monitoring given recent re-starting of methotrexate. It's been 11 months since last bloods, should be 3-monthly whilst on methotrexate. The intervention addresses the duplicate steroid issue but completely omits the critical monitoring requirement for the flagged issue.
    correct: partial

    failure_mode:
    - safety_critical_omission: MedGuard correctly identified the lapsed LFT monitoring for methotrexate in Issue 1 but completely failed to address this in the intervention, instead focusing only on the duplicate topical steroid issue.
</example>

<example>
    Flagged Clinical Issue: Prescription of an NSAID, without co-prescription of an ulcer-healing drug, to a patient with a history of peptic ulceration

    MedGuard Patient Summary: The patient is a 54‑year‑old male with recorded hypertension, COPD/asthma, ischaemic heart disease, and a past peptic ulcer. Recent clinical entries show persistently elevated blood pressures, indicating uncontrolled hypertension. The most recent medication record shows the patient is still taking ibuprofen 200 mg three times daily despite a documented history of peptic ulcer. No gastro‑protective agent is prescribed. There is also no current inhaled therapy for his chronic respiratory disease; the last recorded inhalers (Fostair, Salbutamol, Beclometasone/Formoterol) all have end dates before the SMR and are flagged as not being taken. The combination of untreated hypertension, lack of COPD/asthma treatment, and ongoing NSAID use in a ulcer‑prone patient represents significant safety and therapeutic gaps that require immediate action.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Ibuprofen use in a patient with a history of peptic ulcer
    Evidence provided by MedGuard: Ibuprofen 200 mg tablets taken three times daily and the frailty deficits list a peptic ulcer; no proton‑pump inhibitor or other gastro‑protection is prescribed.
    Clinician reasoning: Correct identification - NSAID use without gastroprotection in patient with peptic ulcer history is a clear safety concern
    The clinician agreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Uncontrolled hypertension with no antihypertensive medication prescribed
    Evidence provided by MedGuard: Multiple blood pressure readings show systolic values >150 mmHg and the patient is on the hypertension register, yet no repeat antihypertensive medication appears in the current medication list.
    Clinician reasoning: Valid concern - BP control is inadequate
    The clinician agreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Absent inhaled therapy for documented COPD/asthma
    Evidence provided by MedGuard: The patient has a COPD/asthma diagnosis and recent symptoms. The last inhaler prescriptions all ended before the SMR and are flagged as not being taken.
    Clinician reasoning: Appropriate identification of missing respiratory therapy
    The clinician agreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: MedGuard correctly identified NSAID use without gastroprotection in Issue 1, which directly matches the flagged issue
    correct: true

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: 1. Discontinue ibuprofen immediately; prescribe paracetamol for analgesia and start a proton‑pump inhibitor (e.g., omeprazole 20 mg daily) for ulcer protection. 2. Initiate antihypertensive therapy – for example, start ramipril 2.5 mg daily (titrate to target BP <140/90) or an alternative guideline‑based agent after assessing renal function and electrolytes. 3. Restart appropriate inhaled treatment for COPD/asthma: prescribe beclometasone 100 µg/formoterol 6 µg inhaler, two actuations twice daily, and a short‑acting rescue inhaler (salbutamol 100 µg) as needed, with a review of inhaler technique at the next visit.

    reasoning: 1. It is illogical to stop the ibuprofen and start a gastroprotective agent at the same time. By stopping we remove the risk factor so PPI not required. I'd also want to know exactly how long ago the ulcer was to inform decision making. Either switch to alternative non-NSAID analgesia OR prescribe PPI with NSAID - not both simultaneously.
    2. Reasonable to want to treat, I would add involve patient in decision making. I'd probably want home readings first (or 24-hour BP monitor)
    3. Agree
    correct: partial

    failure_mode:
    - reasoning_error: MedGuard proposed to simultaneously discontinue ibuprofen AND start a PPI, which is illogical - stopping the NSAID removes the risk factor, making the PPI unnecessary. The correct approach is either switch to non-NSAID analgesia OR continue NSAID with PPI gastroprotection, not both interventions simultaneously.
</example>

<example>
    Flagged Clinical Issue: Concurrent use of warfarin and any antibiotic without monitoring the INR within 5 days

    MedGuard Patient Summary: The patient is a 66‑year‑old female with atrial fibrillation, coronary heart disease, heart failure and hypertension, currently anticoagulated with warfarin (prescribed as 3 mg and 1 mg tablets). Over the past year her INR has been highly unstable, ranging from sub‑therapeutic values (1.4, 1.5, 1.7) to supratherapeutic peaks (3.6, 3.9, 3.1). The target INR for her indication is 2.5. Multiple episodes of flucloxacillin therapy coincide with high INR results, reflecting a known interaction that can potentiate warfarin. The patient also has recurrent hyponatraemia (Na 123 mmol/L, 125 mmol/L) and reports dizziness and falls, which may be contributed to by her antihypertensive regimen (amlodipine 10 mg daily). However, the most serious safety concern is the erratic warfarin control, which places her at significant risk of both thromboembolic events and major bleeding. Given the chronic instability despite regular monitoring, a transition to a direct oral anticoagulant (DOAC) is advisable, provided renal function remains adequate (eGFR 66–74 mL/min/1.73 m²) and there is no mechanical valve. This change would also eliminate the need for frequent INR testing and reduce interaction risk with antibiotics such as flucloxacillin. Other issues (persistent hyponatraemia, anemia, amlodipine dose) should be reviewed, but they do not currently demand an immediate medication change.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Highly unstable warfarin INR with both sub‑therapeutic and supratherapeutic values, increasing risk of stroke and major bleeding
    Evidence provided by MedGuard: INR 1.400, INR 1.500, INR 3.600, INR 3.900, INR 3.100; target INR 2.5 recorded in multiple GP entries
    Clinician reasoning: Correct identification - INR instability is significant and concerning
    The clinician agreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Potential warfarin‑flucloxacillin interaction causing INR spikes
    Evidence provided by MedGuard: Flucloxacillin courses on multiple occasions; INR 3.600 recorded shortly after November course; known interaction between flucloxacillin and warfarin
    Clinician reasoning: Valid concern - this interaction can significantly affect INR
    The clinician agreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Persistent hyponatraemia (serum Na < 125 mmol/L)
    Evidence provided by MedGuard: Na 123 mmol/L, Na 125 mmol/L, Na 126 mmol/L
    Clinician reasoning: Appropriate identification of electrolyte abnormality
    The clinician agreed with MedGuard's assessment of this issue

    Issue 4:
    Issue Identified by MedGuard: Iron‑deficiency anemia with low ferritin
    Evidence provided by MedGuard: Haemoglobin 101 g/L and ferritin 19.7 µg/L; patient on ferrous fumarate 210 mg daily
    Clinician reasoning: Valid concern requiring monitoring
    The clinician agreed with MedGuard's assessment of this issue

    Issue 5:
    Issue Identified by MedGuard: Potential contribution of high‑dose amlodipine to dizziness/falls
    Evidence provided by MedGuard: Amlodipine 10 mg daily prescribed; patient records dizziness and falls; blood pressure 130/60 mmHg
    Clinician reasoning: Reasonable association to consider
    The clinician agreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: MedGuard identified the warfarin-antibiotic interaction in Issue 2, which directly relates to the flagged issue
    correct: true

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: Discontinue warfarin immediately and initiate apixaban 5 mg twice daily (reduce to 2.5 mg twice daily if eGFR falls below 50 mL/min/1.73 m² or if age >80). Provide patient education on DOAC dosing, ensure no contraindications (e.g., mechanical valve, severe liver disease). Arrange renal function test within the next week to confirm dosing. Cancel any pending warfarin repeat prescriptions and update the medication list in the GP system. Document the change and inform the anticoagulation clinic of the transition.

    reasoning: Follow NICE and MHRA guidance on switching to DOAC which has different INR thresholds depending on the choice of DOAC (e.g., to start apixaban INR needs to be below 2) so needs an up to date INR. Should also advise investigation of causes of hyponatraemia. The intervention addresses the anticoagulation instability but fails to follow guideline requirements for safe switching.
    correct: partial

    failure_mode:
    - safety_critical_omission: MedGuard failed to check current INR before switching from warfarin to apixaban, which is essential to avoid overlapping anticoagulation or gaps in coverage that could lead to bleeding or thrombosis.
    - guideline_non_adherence: NICE and MHRA guidance requires checking INR before initiating a DOAC switch - for apixaban, INR must be below 2 before starting. MedGuard's intervention proposes immediate discontinuation without this critical safety check, violating established switching protocols.

    [n.b. You as a reviewer do not have access to the NICE and MHRA guidance, so it's unlikely you'll be able to identify these failure modes with confidence.]
</example>

<example>
    Flagged Clinical Issue: Metformin prescribed to a patient with renal impairment where the eGFR is ≤30 ml/min

    MedGuard Patient Summary: The patient is an 81‑year‑old man with advanced chronic kidney disease (eGFR 14 mL/min/1.73m²), anemia, hypertension, type 2 diabetes, and prostate enlargement. Current repeat medicines are tamsulosin 400 µg MR, atenolol 100 mg, metformin 500 mg BID, allopurinol 300 mg, simvastatin 20 mg nocte, and amlodipine 5 mg daily. Recent vital signs show persistent hypotension (BP 93/61 mmHg and 97/53 mmHg). Laboratory data reveal hyperkalaemia (K⁺ 6.1 mmol/L) and markedly reduced renal function. Metformin is contraindicated at eGFR < 30 mL/min/1.73m², and the current dose of allopurinol exceeds recommended limits for stage 5 CKD. The combination of atenolol, amlodipine and tamsulosin likely contributes to the low blood pressure and raises the risk of symptomatic hypotension. These safety concerns are active and require immediate medication optimisation.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Metformin prescribed despite severe renal impairment (eGFR 14 mL/min/1.73m²)
    Evidence provided by MedGuard: eGFR 14 mL/min/1.73m² recorded while metformin 500 mg BID has been continued.
    Clinician reasoning: eGFR is actually 35 so the dose of metformin is ok. MedGuard has misread the laboratory data.
    The clinician disagreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Atenolol 100 mg contributing to symptomatic hypotension in the context of low BP and poly‑pharmacy with amlodipine and tamsulosin
    Evidence provided by MedGuard: Blood pressure readings of 93/61 mmHg and 97/53 mmHg while on atenolol 100 mg daily, amlodipine 5 mg daily and tamsulosin 400 µg daily.
    Clinician reasoning: Valid concern - triple therapy likely contributing to hypotension
    The clinician agreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Allopurinol dose too high for stage 5 CKD (300 mg daily)
    Evidence provided by MedGuard: Allopurinol 300 mg daily ongoing with eGFR 14 mL/min/1.73m². Guidelines recommend dose ≤100 mg daily when eGFR < 30.
    Clinician reasoning: eGFR is actually 35, not 14. This is based on misread data.
    The clinician disagreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: MedGuard identified metformin in severe renal impairment, but this was based on a hallucinated eGFR of 14 when the actual value is 35. The patient doesn't actually meet the criteria for the flagged issue.
    correct: false

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: 1. Discontinue metformin immediately. 2. Stop atenolol 100 mg and reassess blood pressure; consider titrating amlodipine to the lowest effective dose or alternative antihypertensive if needed. 3. Reduce allopurinol to 100 mg daily (or stop if urate level not target) and arrange urate monitoring. Re‑check serum potassium and renal function within 1 week after changes.

    reasoning: eGFR is 35 so the dose adjustments for metformin and allopurinol are not needed. The intervention for atenolol is reasonable but the other recommendations are based on hallucinated data.
    correct: false

    failure_mode:
    - hallucination: MedGuard fabricated an eGFR value of 14 mL/min/1.73m² when the actual value is 35 mL/min/1.73m², leading to incorrect identification of the flagged issue and inappropriate interventions for metformin and allopurinol dose adjustments.
    - input_processing_error: MedGuard misread or incorrectly extracted the eGFR laboratory value from the patient data, resulting in interventions based on false information that don't address the patient's actual clinical needs.
</example>

<example>
    Flagged Clinical Issue: Combined hormonal contraceptive prescribed to woman with body mass index of ≥40

    MedGuard Patient Summary: The patient is a 35‑year‑old woman with a history of chronic low back pain, multiple spinal procedures and long‑term intermittent opioid use. At the time of the SMR she is actively prescribed two medications: (1) Codeine 30 mg tablets PRN and (2) an Evra combined hormonal contraceptive patch. She has a documented hypertension deficit but recent BP readings are within normal range (130/65 mmHg). A weight record shows 160 kg (BMI 58.8), indicating severe obesity, which is a risk factor for cardiovascular disease and may affect analgesic choice. No other chronic repeat medicines are listed. The patient's opioid exposure is extensive: large cumulative prescriptions of codeine (multiple courses from 2019‑2023, most recent ongoing) and prior tramadol and morphine use, suggesting dependence risk. Current use of codeine for chronic back pain is not guideline‑recommended and carries safety concerns (opioid dependence, constipation, respiratory depression, especially in the context of severe obesity). The contraceptive patch is appropriate given the patient is a non‑smoker and has no documented VTE history, though counseling about obesity‑related VTE risk may be warranted. Overall, the major medication safety issue is the inappropriate chronic use of codeine.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Inappropriate chronic use of codeine for ongoing low back pain, posing risk of opioid dependence and adverse effects
    Evidence provided by MedGuard: Codeine 30 mg tablets prescribed and recorded as being taken at the SMR. Historical records document multiple long‑term codeine courses spanning 2019‑2023, indicating substantial cumulative exposure. Current weight/BMI of 160 kg (BMI 58.8) increases risk of opioid‑related respiratory depression.
    Clinician reasoning: Valid concern regarding chronic opioid use for non-malignant pain
    The clinician agreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: MedGuard completely missed the contraindication for CHC at BMI ≥40, instead focusing exclusively on opioid use. The patient summary even incorrectly states "The contraceptive patch is appropriate" which is incorrect given the BMI of 58.8. This is a critical safety omission as CHC at this BMI significantly increases VTE risk.
    correct: false

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: Discontinue codeine immediately. Arrange a same‑day referral to the multidisciplinary pain team for assessment and initiation of an evidence‑based pain management plan (e.g., physiotherapy, NSAID if not contraindicated, or alternative non‑opioid analgesics). Provide the patient with information on opioid withdrawal symptoms and arrange a follow‑up appointment within 1 week to assess pain control and manage withdrawal if needed.

    reasoning: Unfortunately, pain team waiting lists range from 12-18 months. Abrupt discontinuation of opioid will cause withdrawal and unlikely to be effective without extensive support and education. More critically, this intervention doesn't address the flagged CHC contraindication at all. The appropriate intervention should be sexual health/contraceptive counselling regarding alternative contraception.
    correct: false

    failure_mode:
    - confidence_calibration_error: MedGuard was overconfident about opioid cessation being the primary concern and proposed immediate discontinuation without realistic consideration of withdrawal management or healthcare system constraints (12-18 month pain team waiting lists), while completely missing the actual flagged safety issue.
    - knowledge_gap: MedGuard failed to recognize that CHC is contraindicated at BMI ≥40 due to significantly increased VTE risk, despite the patient having BMI 58.8. The patient summary even incorrectly stated the contraceptive patch was "appropriate," demonstrating a fundamental gap in contraceptive safety knowledge.
</example>

<example>
    Flagged Clinical Issue: Methotrexate prescribed without folic acid

    MedGuard Patient Summary: The 75‑year‑old female has chronic hypertension, CKD stage 3 (eGFR ~50 mL/min), rheumatoid arthritis, osteoporosis and a history of peptic ulcer. Current repeat medications are rosuvastatin 5 mg alternate days, bisoprolol 2.5 mg twice daily, amlodipine 5 mg daily, risedronate 35 mg weekly, omeprazole 20 mg daily, calcium chewable tablets twice daily, co‑codamol 8 mg/500 mg PRN (up to four times daily) and methotrexate 20 mg weekly. Recent labs show stable haematology, normal liver enzymes, normal potassium and a creatinine of 97 µmol/L (eGFR 49.5 mL/min). Blood pressure remains suboptimally controlled with clinic readings as high as 172/80 mmHg despite two antihypertensives. No folic acid prescription is recorded with methotrexate, and the patient is on calcium supplementation that should be separated from weekly risedronate dosing. Overall, the medication regimen is largely appropriate, but a clear safety gap exists regarding folic acid protection for methotrexate therapy.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Missing folic acid supplementation for methotrexate therapy
    Evidence provided by MedGuard: Methotrexate 20 mg weekly with no record of folic acid prescription; folic acid is recommended to reduce methotrexate toxicity, especially in CKD.
    Clinician reasoning: Correct identification - folic acid is essential with methotrexate therapy
    The clinician agreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Uncontrolled hypertension despite two agents
    Evidence provided by MedGuard: Clinic blood pressures of 172/80 mmHg and 174/86 mmHg, while home averages were 141/69 mmHg. Patient is on bisoprolol 2.5 mg BID and amlodipine 5 mg daily, without ACE‑I/ARB.
    Clinician reasoning: Home average is most reliable and it is fine, target <140/80 in a non diabetic. Clinic readings may reflect white coat effect.
    The clinician disagreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Potential additive bradycardia/hypotension from combined bisoprolol and amlodipine
    Evidence provided by MedGuard: Both bisoprolol 2.5 mg BID and amlodipine 5 mg daily are active; co‑prescription can increase risk of bradycardia or hypotension, though current heart rate is not recorded.
    Clinician reasoning: Partially correct. Amlodipine doesn't slow heart rate. Dual can cause hypotension but this is not the case here.
    The clinician disagreed with MedGuard's assessment of this issue

    Issue 4:
    Issue Identified by MedGuard: Timing conflict between risedronate and calcium supplement
    Evidence provided by MedGuard: Risedronate 35 mg weekly requires an empty stomach; calcium chewable tablets (Calceos) are taken twice daily. Concurrent intake can impair bisphosphonate absorption.
    Clinician reasoning: Valid concern about timing of administration
    The clinician agreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue
    
    reasoning: MedGuard correctly identified the missing folic acid in Issue 1, which directly matches the flagged issue
    correct: true

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: Start folic acid 5 mg orally once weekly (e.g., take the day after the methotrexate dose) to provide protective supplementation and reduce the risk of methotrexate‑induced bone‑marrow or hepatic toxicity.

    reasoning: The intervention correctly addresses the flagged issue and is appropriate. However, should also flag that omeprazole is potentially unnecessary - long-term PPI use may not be indicated.
    correct: true

    failure_mode:
    - non_critical_omission: While MedGuard correctly addressed the flagged folic acid deficiency, the intervention missed the opportunity to review the ongoing necessity of omeprazole - long-term PPI use may not be indicated in this patient and represents a potential deprescribing opportunity.
</example>

<example>
    Flagged Clinical Issue: Metformin prescribed to a patient with renal impairment where the eGFR is ≤30 ml/min

    MedGuard Patient Summary: The 68‑year‑old male with atrial fibrillation, heart failure, CKD stage 3b (eGFR 46 mL/min/1.73m2, creatinine 135 µmol/L), type 2 diabetes, hypertension and anemia is currently taking metformin, gliclazide, ramipril, apixaban 5 mg BID, bisoprolol, linagliptin, digoxin 125 µg daily and atorvastatin. Recent labs show CKD progression, hyperkalaemia (K⁺ 5.1 mmol/L), iron‑deficiency anaemia (Ferritin 9 µg/L, transferrin saturation 10%, Hb 115 g/L). The apixaban dose exceeds renal dosing recommendations (creatinine ≥133 µmol/L meets a dose‑reduction criterion). Digoxin at 125 µg daily is high for eGFR < 50 mL/min and predisposes to toxicity. Iron deficiency is untreated. These issues pose significant safety risks and require immediate medication adjustment and initiation of iron therapy.

    MedGuard Identified the following issues, all of which were then reviewed by a trained clinician to assess their correctness:

    Issue 1:
    Issue Identified by MedGuard: Apixaban dose exceeds renal dosing recommendation
    Evidence provided by MedGuard: Creatinine 135 µmol/L and eGFR 46 mL/min/1.73m2; current apixaban 5 mg twice daily
    Clinician reasoning: Needs to meet TWO of the dose adjustment criteria, patient only meets 1 (they are age >80, body weight <60kg, creatinine >133). Unless compelling alternative reason (e.g., serious major bleed in the past) for dose reduction, the current apixaban dose is ok. MedGuard has misunderstood the dose reduction criteria.
    The clinician disagreed with MedGuard's assessment of this issue

    Issue 2:
    Issue Identified by MedGuard: Digoxin dose potentially unsafe in CKD stage 3b
    Evidence provided by MedGuard: eGFR 46 mL/min/1.73m2 with digoxin 125 µg daily
    Clinician reasoning: Valid concern in context of reduced renal function
    The clinician agreed with MedGuard's assessment of this issue

    Issue 3:
    Issue Identified by MedGuard: Untreated iron‑deficiency anaemia
    Evidence provided by MedGuard: Ferritin 9 µg/L, transferrin saturation 10%, Hb 115 g/L
    Clinician reasoning: Important to rectify in heart failure, she may qualify for ferrinject infusion if oral iron not tolerated
    The clinician agreed with MedGuard's assessment of this issue

    Issue 4:
    Issue Identified by MedGuard: Gliclazide dose may cause hypoglycaemia in CKD
    Evidence provided by MedGuard: Gliclazide 80 mg twice daily with eGFR 46 mL/min/1.73m2
    Clinician reasoning: Valid concern requiring monitoring
    The clinician agreed with MedGuard's assessment of this issue

    Issue 5:
    Issue Identified by MedGuard: Metformin continued despite reduced renal function
    Evidence provided by MedGuard: Metformin 500 mg tablets with eGFR 46 mL/min/1.73m2
    Clinician reasoning: eGFR 46 not a contraindication to metformin, max 500mg BD would be ok
    The clinician disagreed with MedGuard's assessment of this issue

    The clinician then considered whether MedGuard correctly identified the flagged issue

    reasoning: The patient's eGFR is 46, not ≤30, so this flagged issue doesn't apply to this patient. MedGuard failed to recognize this threshold error.
    correct: false

    The clinician then considered whether MedGuard's intervention would be appropriate for the patient:

    MedGuard believed an intervention was required

    MedGuard's intervention: 1. Reduce apixaban to 2.5 mg twice daily (dose‑adjusted for creatinine ≥133 µmol/L). 2. Reduce digoxin to 62.5 µg daily (or 0.0625 mg) and arrange a serum digoxin level within 1 week, with further monitoring of renal function and electrolytes. 3. Start oral iron therapy (e.g., ferrous sulfate 200 mg elemental iron three times daily) and repeat full blood count, ferritin and transferrin saturation in 4 weeks to assess response.

    reasoning: 1. Doesn't qualify for dose adjustment - requires TWO of the three criteria (age >80, weight <60kg, creatinine >133), not just one. This is a quantitative error in understanding the dose reduction criteria.
    2. Agree reasonable to reduce digoxin
    3. Agree re trial of oral iron
    correct: partial

    failure_mode:
    - quantitative_error: MedGuard misunderstood the apixaban dose reduction criteria, incorrectly believing that meeting ONE criterion (creatinine >133 µmol/L) was sufficient when the guidelines require TWO of three criteria (age >80, weight <60kg, creatinine >133) to be met for dose reduction.
    - input_processing_error: MedGuard failed to recognize that the patient's eGFR of 46 mL/min/1.73m2 does not meet the flagged issue threshold of ≤30 ml/min, resulting in incorrect identification of the flagged issue and an unnecessary intervention regarding metformin.
</example>
"""
